Retrospective analysis with metronomic chemotherapy in patients with metastatic renal cell carcinoma.

Abstract

e15144 Background: Treatment of metastatic kidney cancer is based on antiangiogenic therapy; although this treatment is expensive and secondary effects could be important. There are many ways to block angiogenic process, metronomic chemotherapy is one of them. We evaluate response to metronomic chemotherapy as well toxicity. Methods: Patients characteristics: We analyzed medical records with kidney cancer,all patients received at least 3 cycles of the treatment. All patients where classified according to Motzer criteria: good/ intermediate/poor prognosis were: 6/6/1 respectively. Response according to RECIST were: Partial response 3 pts (23.7 %) one patient with good prognostic and two intermediate, stable disease in 7 (53.84 %) (4 good and 3 intermediate prognosis), progression disease were in 3 patients (1 with good, 2 with poor prognosis). In 84% patients we noted clinical benefit with tree cycles. The median time to disease progression for the entire group was 8 months (range, 1-11 mos), with a median overall survival of 11 months (range 2-24mos). The toxicity grade 3-4 reported was in 3 patients: gastrointestinal, dermatological, and febrile neutropenia. Additional patients had reversible toxicities grade 1-2 including alopecia, nausea, vomiting, and fatigue in 90% of the cases. Results: Metronomic chemotherapy is a good therapeutic option in patients with metastatic kidney cancer with acceptable response rate. Conclusions: Metronomic chemotherapy is a good therapeutic option in patients with metastatic kidney cancer with acceptable response rate. No significant financial relationships to disclose.